Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fentanyl + tramadol is a combination of two opioid analgesics used together for the management of moderate to severe pain, particularly in clinical settings such as anesthesia or procedural sedation. Fentanyl is a potent synthetic opioid agonist with high affinity for the μ-opioid receptor, providing rapid and strong analgesia. Tramadol is an atypical centrally acting synthetic opioid that acts as a weak μ-opioid receptor agonist and also inhibits the reuptake of serotonin and norepinephrine, contributing to its analgesic effects through both opioid and monoaminergic pathways. The combination may be used in specific medical procedures (e.g., awake endotracheal intubation) to leverage their complementary mechanisms for effective pain control while aiming to minimize respiratory depression compared to higher doses of single agents. However, co-administration increases the risk of serotonin syndrome due to additive serotonergic effects, as well as other adverse events such as cardiac arrhythmias[2][5]. This combination should only be administered under close medical supervision.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on fentanyl + tramadol.